Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

• Awaiting development
• Reference number: GID-TA11971
• Expected publication date: TBC